Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

BACKGROUND: Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. Trotabresib, a novel bromodomain and extraterminal inhibitor, ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieito, Maria, Simonelli, Matteo, de Vos, Filip, Moreno, Victor, Geurts, Marjolein, Lorenzi, Elena, Macchini, Marina, van den Bent, Martin J, Del Conte, Gianluca, de Jonge, Maja, Martín-Soberón, Maria Cruz, Amoroso, Barbara, Sanchez-Perez, Tania, Zuraek, Marlene, Hanna, Bishoy, Aronchik, Ida, Filvaroff, Ellen, Chang, Henry, Mendez, Cristina, Arias Parro, Marina, Wei, Xin, Nikolova, Zariana, Sepulveda, Juan Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653173/
https://www.ncbi.nlm.nih.gov/pubmed/36382109
http://dx.doi.org/10.1093/noajnl/vdac146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653173/
https://www.ncbi.nlm.nih.gov/pubmed/36382109
http://dx.doi.org/10.1093/noajnl/vdac146

Ejemplares similares